Alzheimer Disease Clinical Trial
— XanaMIAOfficial title:
A Phase 2b, Double-Blind, Placebo-Controlled, Parallel-Groups, 36-Week, 2-Arm Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem® 10 mg Daily in Patients With Mild or Moderate Dementia Due to Alzheimer's Disease
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion.
Status | Recruiting |
Enrollment | 220 |
Est. completion date | December 2025 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: - Male or female aged 50 years or older, inclusive at the time of Screening. - Clinical syndrome of mild or moderate dementia, likely to be due to AD in the opinion of the Investigator, at Screening, including meeting the following criteria: 1. Clinical Dementia Rating (CDR) global score of 0.5 to 1.0 2. Mini-mental state examination (MMSE) score of 18 to 26 3. Magnetic resonance imaging (MRI) or computerized tomography (CT) scan within 1 year prior to randomization that excludes alternative diagnoses for dementia such as large stroke, likely vascular dementia, brain tumor, subdural hematoma, or other non-AD dementia type findings 4. Positive plasma AD biomarker signature at Pre-screening, comprising fasting levels of a tau species protein. 5. Cognitive impairment on a symbol coding test of at least 0.5 standard deviations (SD) below the normative data at Screening. - If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to Screening. - Has a consenting trial partner who, in the Investigator's judgment, has frequent and sufficient contact with the participant to be able to provide accurate information as to the participant's cognitive and functional abilities. The trial partner must be available to provide information to the Investigator and trial site staff about the participant and agrees to attend all trial site visits in person for scale completion. A trial partner should be available for the duration of the trial. The measure of adequate availability will be at the Investigator's discretion. - Participants must be able to comfortably abstain from caffeine intake for 4 hours prior to scheduled cognitive assessments. - Smokers are eligible if they are able to comfortably abstain from nicotine / tobacco products for 2 hours prior to scheduled cognitive assessments. - Must provide written informed consent to participate in the trial and be willing and able to participate for the maximum of 9 months of treatment and up to 11.5 months of site visits. Exclusion Criteria: - Use of anti-amyloid or anti-tau antibody within 6 months. - Diagnosis of a non-AD dementia including traumatic brain injury. - Diagnosis of an active major mental illness of concern in the opinion in the Investigator, including major depressive disorder, bipolar illness, or schizophrenia. - Participation in another clinical trial of a drug or device - Has a body mass index or body weight that will interfere with participation in the trial, including inadequate venous access to complete the trial assessments, to be determined at the discretion of the Investigator. - Previous clinically significant systemic illness or infection, including test positive COVID-19, within the past 4 weeks prior to Screening. - Clinical diagnosis of Type I or Type II diabetes requiring insulin. - Exhibit physical, cognitive, or language impairments, in the opinion of the Investigator, of such severity as to adversely affect the validity of the data derived from the neuropsychological tests. - Trial participants with evidence of current infection with HIV, hepatitis B, or hepatitis C. - Participants with a history of clinically significant drug abuse or addiction in the past 2 years - Evidence or history of alcohol abuse |
Country | Name | City | State |
---|---|---|---|
Australia | ACW Investigative Site 113 | Birtinya | Queensland |
Australia | ACW Investigative Site 105 | Chermside | Queensland |
Australia | ACW Investigative Site 106 | Darlinghurst | New South Wales |
Australia | ACW Investigative Site 103 | Erina | New South Wales |
Australia | ACW Investigative Site 101 | Ivanhoe | Victoria |
Australia | ACW Investigative Site 102 | Kogarah | New South Wales |
Australia | ACW Investigative Site 107 | Macquarie Park | New South Wales |
Australia | ACW Investigative Site 108 | Malvern | Victoria |
Australia | ACW Investigative Site 104 | Nedlands | Western Australia |
Australia | ACW Investigative Site 111 | Newcastle | New South Wales |
Australia | ACW Investigative Site 112 | Parkville | Victoria |
Australia | ACW Investigative Site 109 | West Perth | Western Australia |
Australia | ACW Investigative Site 110 | Woodville South | South Australia |
Lead Sponsor | Collaborator |
---|---|
Actinogen Medical |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effects of 10 mg Xanamem on cognition | Change from Baseline to end of treatment (EOT) in a custom global cognitive test battery (CTB). The global CTB is calculated as an average Z-score, with higher scores indicating improvement. | 36 weeks | |
Primary | Incidence and severity of treatment-emergent adverse events (TEAEs) [safety and tolerability of Xanamem] | Incidence and severity of TEAEs | 36 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |